Tag: Gp41

Enfuvirtide was the first drug approved in the fusion inhibitor class of antiretrovirals, marking a new approach in HIV treatment. This synthetic peptide is used as part of a combination therapy for patients with multidrug-resistant HIV-1 infection, and its classification highlights its unique mechanism of blocking viral entry.

Approved by the FDA in 2003, enfuvirtide (Fuzeon) was the first HIV fusion inhibitor to be introduced, representing a new class of antiretroviral drugs. The mechanism of action of enfuvirtide involves a unique, extracellular approach to inhibit the fusion of the human immunodeficiency virus (HIV) with healthy host cells, thereby preventing viral replication.

Enfuvirtide was the first HIV fusion inhibitor approved by the FDA in 2003, establishing a novel class of antiretroviral drugs for treatment-experienced patients. This article explains precisely **how does enfuvirtide prevent this step in the viral infection cycle** by blocking the final stages of viral entry.

Enfuvirtide, the first-in-class HIV fusion inhibitor, was approved by the U.S. FDA on March 13, 2003 [1.9.1, 1.9.3]. It represents a unique class of antiretroviral drugs. So, what is the target of enfuvirtide? Its action is highly specific, targeting a critical component of the virus itself.

Approved by the FDA in 2003, enfuvirtide became the first HIV fusion inhibitor on the market, offering a new treatment option for highly treatment-experienced patients. Its unique mechanism of action provided a vital new tool in the fight against multi-drug-resistant HIV.